Who
Shaun Bagai
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, RenovoRx.
In numbers
- Trades disclosed
- 23
- Buys
- 10
- Sells
- 0
- Bought
- $53K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 30 Sep 2021
- Last trade
- 3 Apr 2026
- Last filed
- 7 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Apr 2026filed 7 Apr 2026 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code A | —946,107 at $0.00 | filing |
| 3 Apr 2026filed 7 Apr 2026 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code A | —946,107 at $0.00 | filing |
| 20 Mar 2026filed 24 Mar 2026 | RNXT RenovoRxBiotechnology | SEC FORM 4 Bought | —24,300 | filing |
| 20 Mar 2026filed 24 Mar 2026 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code P | —12,150 | filing |
| 20 Mar 2026filed 24 Mar 2026 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code P | —12,150 | filing |
| 20 Mar 2026filed 24 Mar 2026 | RNXT RenovoRxBiotechnology | SEC FORM 4 Bought | —24,300 | filing |
| 18 Dec 2025filed 22 Dec 2025 | RNXT RenovoRxBiotechnology | SEC FORM 4 Bought | $4,5005,000 at $0.90 | filing |
| 17 Dec 2025filed 19 Dec 2025 | RNXT RenovoRxBiotechnology | SEC FORM 4 Bought | $4,2505,000 at $0.85 | filing |
| 25 Aug 2025filed 26 Aug 2025 | RNXT RenovoRxBiotechnology | SEC FORM 4 Bought | $4,5505,000 at $0.91 | filing |
| 22 Aug 2025filed 26 Aug 2025 | RNXT RenovoRxBiotechnology | SEC FORM 4 Bought | $4,7505,000 at $0.95 | filing |
| 1 Jul 2025filed 3 Jul 2025 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code A | —102,498 at $0.00 | filing |
| 15 Apr 2025filed 16 Apr 2025 | RNXT RenovoRxBiotechnology | SEC FORM 4 Bought | $6,8257,500 at $0.91 | filing |
| 14 Apr 2025filed 16 Apr 2025 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code A | —409,992 at $0.00 | filing |
| 9 Apr 2025filed 10 Apr 2025 | RNXT RenovoRxBiotechnology | SEC FORM 4 Bought | $8,30010,000 at $0.83 | filing |
| 7 Apr 2025filed 8 Apr 2025 | RNXT RenovoRxBiotechnology | SEC FORM 4 Bought | $8,30010,000 at $0.83 | filing |
| 26 Jan 2024filed 30 Jan 2024 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code P | —40,983 | filing |
| 26 Jan 2024filed 30 Jan 2024 | RNXT RenovoRxBiotechnology | SEC FORM 4 Bought | —40,983 | filing |
| 19 Jan 2024filed 23 Jan 2024 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code A | —66,973 at $0.00 | filing |
| 19 Jan 2024filed 23 Jan 2024 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,263 at $0.00 | filing |
| 15 Mar 2023filed 29 Mar 2023 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code A | —130,000 at $0.00 | filing |
News
RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP TrialRNXT · manilatimes.net · 7 Oct 2026
0 headlines in the last 90 days name Shaun Bagai; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.